Opus Genetics (NASDAQ:IRD) CEO George Magrath Sells 9,511 Shares

Opus Genetics, Inc. (NASDAQ:IRD) CEO George Magrath sold 9,511 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $5.22, for a total value of $49,647.42. Following the sale, the chief executive officer owned 1,741,344 shares of the company’s stock, valued at approximately $9,089,815.68. This represents a 0.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

George Magrath also recently made the following trade(s):

• On Monday, March 16th, George Magrath sold 24,438 shares of Opus Genetics stock. The stock was sold at an average price of $5.21, for a total value of $127,321.98.

Opus Genetics Stock Down 2.1%

Shares of NASDAQ:IRD opened at $5.12 on Tuesday. Opus Genetics, Inc. has a 12-month low of $0.81 and a 12-month high of $5.81. The stock has a market cap of $365.57 million, a PE ratio of -6.24 and a beta of 0.52. The business has a 50 day moving average of $4.70 and a 200-day moving average of $3.09.

Key Stories Impacting Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Neutral Sentiment: Management will present at several ophthalmology and industry conferences in May 2026, maintaining visibility with investors and the research community; this is routine corporate outreach rather than an immediate clinical readout. Opus Genetics to Participate in Leading Medical Conferences in May 2026
• Negative Sentiment: Multiple insiders sold stock on April 23rd (CEO George Magrath, CFO Robert Gagnon, COO Joseph Schachle, President Benjamin Yerxa, and others). Combined sales total tens of thousands of shares at roughly $5.18–$5.24 per share. While the company discloses these were sales to cover tax withholding on vested awards (reducing the likelihood of a signal of loss of confidence), clustered insider selling can pressure the share price and likely contributed to today’s weakness. SEC filings: CEO sale CEO Form 4, CFO sale CFO Form 4, other insider filings available in SEC disclosures.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Cantor Fitzgerald initiated coverage on Opus Genetics in a report on Monday, March 30th. They set an “overweight” rating and a $15.00 price objective for the company. Wall Street Zen upgraded shares of Opus Genetics from a “sell” rating to a “hold” rating in a research report on Sunday, March 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Opus Genetics in a research report on Tuesday, April 21st. BTIG Research increased their target price on shares of Opus Genetics from $7.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Wedbush increased their target price on shares of Opus Genetics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.11.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in IRD. Comerica Bank acquired a new position in shares of Opus Genetics during the 1st quarter worth approximately $29,000. Royal Bank of Canada acquired a new stake in shares of Opus Genetics during the 1st quarter worth approximately $299,000. Nantahala Capital Management LLC boosted its position in shares of Opus Genetics by 6.0% during the 2nd quarter. Nantahala Capital Management LLC now owns 3,345,923 shares of the company’s stock worth $3,152,000 after acquiring an additional 188,028 shares in the last quarter. Mink Brook Asset Management LLC boosted its position in shares of Opus Genetics by 47.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 1,197,616 shares of the company’s stock worth $1,128,000 after acquiring an additional 387,536 shares in the last quarter. Finally, Opaleye Management Inc. boosted its position in shares of Opus Genetics by 3.8% during the 2nd quarter. Opaleye Management Inc. now owns 1,220,000 shares of the company’s stock worth $1,149,000 after acquiring an additional 45,000 shares in the last quarter. Institutional investors and hedge funds own 14.97% of the company’s stock.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.